News articles about Strongbridge Biopharma (NASDAQ:SBBP) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Strongbridge Biopharma earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.3502884250798 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of equities research analysts have issued reports on the company. BidaskClub downgraded Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research report on Thursday, January 18th. Zacks Investment Research downgraded Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. Finally, Cantor Fitzgerald set a $14.00 price target on Strongbridge Biopharma and gave the company a “buy” rating in a research report on Wednesday, January 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. Strongbridge Biopharma has an average rating of “Hold” and an average target price of $12.81.
Shares of Strongbridge Biopharma (NASDAQ SBBP) opened at $6.80 on Friday. Strongbridge Biopharma has a 1 year low of $2.45 and a 1 year high of $9.02. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89. The firm has a market capitalization of $271.07, a PE ratio of -2.00 and a beta of 1.98.
Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.07. research analysts expect that Strongbridge Biopharma will post -2.86 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Strongbridge Biopharma (SBBP) Earning Somewhat Favorable Press Coverage, Analysis Finds” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/17/strongbridge-biopharma-sbbp-earning-somewhat-favorable-press-coverage-analysis-finds.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.